Anatomic Pathology Billing 2026: Surgical Pathology Levels, the Professional/Technical Split, and the Anti-Markup Rule OIG Actually Enforces

By Rcmaxis Revenue Cycle Team  ·  September 2026  ·  13 min read

Surgical pathology billing runs on a six-level complexity scale, from a simple specimen requiring minimal gross and microscopic examination up to the most complex resections requiring extensive tissue processing and interpretation — and the level assigned has to match the actual documented complexity of what the pathologist examined, not a default level the lab's system applies to a given specimen type regardless of what that specific specimen actually required.

This guide covers the surgical pathology level system and where conservative coding habits leave real revenue unbilled, the professional-versus-technical component split that determines who bills what, and the anti-markup rule that governs referred pathology services — an enforcement area OIG has treated as a standing priority for years, not a one-time review cycle.

The Six-Level Surgical Pathology Scale

CPT 88302 through 88309 assign surgical pathology specimens to one of six complexity levels based on the gross and microscopic examination actually required — not the specimen's general category, but the specific work the pathologist performed and documented on that specimen.

The failure pattern in high-volume labs isn't usually a single dramatic miscode — it's a systemic default where a lab's information system pre-assigns a level to a specimen type based on the most common historical assignment for that type, and the pathologist's actual documented findings for a specific, more complex case never override that default because nobody's checking each case against its assigned level before the claim goes out.

The Professional and Technical Component Split

Surgical pathology billing splits into a technical component (specimen processing, slide preparation) and a professional component (the pathologist's interpretation), and getting the modifier usage right on this split determines whether the right party gets paid for the right piece of the service.

Group practices and hospital-based pathology arrangements where processing and interpretation happen at different sites need a clear, current agreement about which component each party bills — and that agreement needs to be revisited whenever a referral pattern or lab arrangement changes, not set once and assumed to still apply years later.

This matters more than it might seem for a purely administrative split, because the component that actually gets billed determines which entity is on the hook if a claim is later questioned. A hospital-based pathologist billing only the professional component under modifier 26, while the hospital's own lab bills the technical component separately under its facility contract, creates two independent claims that each need to stand on their own documentation — and a gap in either one doesn't get quietly absorbed by the other.

The Anti-Markup Rule: A Standing OIG Enforcement Priority

The anti-markup rule prohibits a physician or practice from billing more for a purchased diagnostic test — including anatomic pathology interpretations performed by an outside pathologist — than the actual amount paid to the performing entity, or the fee schedule amount, whichever is lower. This isn't a niche technicality; it's one of the more consistently enforced integrity rules specifically because pathology and radiology referral arrangements create an obvious financial incentive to mark up a purchased service.

The compliance position that holds up under review is straightforward on paper even though the underlying business arrangements can get complicated: know exactly what's actually paid to the performing pathologist or lab for each purchased interpretation, and never bill the payer more than that amount or the applicable fee schedule rate, whichever is lower — documented, not just assumed to be handled correctly because the billing software doesn't flag an obvious error.

Immunohistochemistry and Add-On Code Bundling

Immunohistochemistry (CPT 88342 and related add-on codes) is billed per antibody stain, and a specimen requiring a panel of multiple stains generates multiple line items — but bundling edits and per-specimen limits mean these claims need specific attention to avoid both under- and over-billing.

Common Anatomic Pathology Denial Patterns

• Surgical pathology level defaulted by specimen type rather than actual documented complexity: Fixed by checking each case's specific findings against the level system before the claim goes out, not relying on a system default.
• Professional/technical component modifier mismatched to which entity performed which part: Fixed by maintaining a current, documented agreement on component billing for every referral arrangement.
• Purchased pathology interpretations billed above the anti-markup rule's allowed amount: Fixed by documenting the actual amount paid to the performing pathologist for every purchased interpretation.
• Immunohistochemistry stains billed without matching documentation of each antibody performed: Fixed by ensuring the pathology report explicitly lists every stain and its diagnostic purpose.

Anatomic pathology billing has more structural complexity packed into a small number of code families than most specialties — a six-level complexity scale, a professional/technical split that depends on who's actually doing what, and an anti-markup rule that carries real enforcement weight behind it — which means the labs and groups that stay clean aren't necessarily the most sophisticated coders, they're the ones with a documented process for checking each of these three things on every claim rather than assuming last quarter's pattern still holds. Given how directly the anti-markup rule ties back to referral relationships that can shift without anyone updating the billing agreement behind them, that's the one worth checking first. A quarterly review of every active referral arrangement — who performs the technical work, who interprets, and what's actually paid versus what's actually billed — catches a drifted agreement long before a payer's program integrity unit finds it first, and costs a fraction of what a multi-year recoupment demand would.